# Phase 1 Small Cell Lung Carcinoma trials: 46 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 46 trials in phase 1 for Small Cell Lung Carcinoma that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 1 Small Cell Lung Carcinoma trials: 46 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-1/small-cell-lung-carcinoma

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 46
- Recruiting or not yet: 46
- Read on: November 19, 2026

## Trials

The 25 newest of 46, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 17, 2026 | NCT07940881 | A Multicenter, Open-label, Phase 1/1b, Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SI-B037 in Solid Tumors | SystImmune Inc. | Phase 1 | Recruiting | Locally Advanced /Metastatic Solid Tumors, Locally Advanced / Metastatic Solid Tumors, First in Human, Metastatic Solid... | 400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07940881) |
| November 2, 2026 | NCT07908667 | A Study of TRB191 in Patients With Extensive-stage Small Cell Lung Cancer | Novartis Pharmaceuticals | Phase 1 | Recruiting | Extensive-stage Small Cell Lung Cancer | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07908667) |
| October 23, 2026 | NCT07892625 | A Phase I Study of HS-20093 in Combination With ZG006 With or Without Adebrelimab in Patients With ES-SCLC | Hansoh BioMedical R&D Company | Phase 1 | Not yet recruiting | Extensive Stage Small Cell Lung Cancer (ES-SCLC) | 338 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07892625) |
| October 22, 2026 | NCT07890246 | A Phase 1 Study of IM-1340 in Participants With Advanced Cancer | Immunome, Inc. | Phase 1 | Not yet recruiting | Colorectal Cancer, Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Neuroendocrine Neoplasm | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07890246) |
| October 21, 2026 | NCT07886047 | Propranolol Hydrochloride Combined With Adebrelimab and Platinum-Based Chemotherapy in Small Cell Lung Cancer | Second Xiangya Hospital of Central South University | Phase 1 | Recruiting | Small Cell Lung Cancer (SCLC) | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07886047) |
| August 24, 2026 | NCT07783477 | A Study of Armored CAR T Cells in People With Cancer | Memorial Sloan Kettering Cancer Center | Phase 1 | Recruiting | Neuroendocrine Cancer, Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ) | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07783477) |
| July 20, 2026 | NCT07713732 | TLN-499 in Combination With Venetoclax in Patients With Relapsed/Refractory Solid Tumors | Treeline Biosciences, Inc. | Phase 1 | Recruiting | Small Cell Lung Cancer ( SCLC ), Neuroendocrine Cancer, Malignant Pleural Mesotheliomas (Mpm), Synovial Sarcomas | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07713732) |
| June 12, 2026 | NCT07646106 | THE-0504 in Patients With Solid Tumors | Thena Biotech S.r.l. | Phase 1 | Recruiting | Small Cell Lung Cancer (SCLC), Colorectal Carcinoma (CRC), Gastric Cancer (GC), Triple -Negative Breast Cancer... | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07646106) |
| June 3, 2026 | NCT07623369 | A First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid Tumors | Huahui Health | Phase 1 | Recruiting | Solid Tumor, Non-small Cell Lung Cancer, Hepatocellular Carcinoma, Colorectal Cancer, Head and Neck Squamous Cell... | 299 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07623369) |
| April 30, 2026 | NCT07559019 | Safety and Preliminary Activity of BI115 in Advanced SCLC | Innovent Biologics (Suzhou) Co. Ltd. | Phase 1 | Recruiting | Small Cell Lung Cancer (SCLC) | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07559019) |
| April 24, 2026 | NCT07550842 | A Clinical Study for the Safety and Efficacy of BL0020 Injection in Combination With Toripalimab Injection in Patients With Recurrent... | Shanghai Best-Link Bioscience, LLC | Phase 1 | Not yet recruiting | Small Cell Carcinoma of Lung | 33 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07550842) |
| April 22, 2026 | NCT07545954 | DSP-0390 in Combination With Atezolizumab for Small Cell Lung Cancer | Washington University School of Medicine | Phase 1 | Recruiting | Small-cell Lung Cancer, Small Cell Lung Cancer Extensive Stage | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07545954) |
| April 15, 2026 | NCT07531095 | Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC) | Amgen | Phase 1 | Recruiting | Small Cell Lung Cancer | 160 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07531095) |
| April 8, 2026 | NCT07517198 | Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors | Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. | Phase 1 | Recruiting | Solid Tumor, Small Cell Lung Cancer (SCLC), High Grade Neuroendocrine Cancer, Small Cell Carcinomas of Non-lung Origin... | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07517198) |
| April 3, 2026 | NCT07509034 | Autologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cancer With Recurrent or... | National Cancer Institute (NCI) | Phase 1 | Recruiting | Recurrent Small Cell Lung Cancer, Extensive-Stage Small Cell Lung Cancer, Small Cell Lung Cancer, Small Cell Lung... | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07509034) |
| March 23, 2026 | NCT07488923 | A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC... | Moonlight Bio, Inc | Phase 1 | Recruiting | Small Cell Lung Cancer (SCLC ), Extrapulmonary Neuroendocrine Carcinoma (EP-NEC), Gastroenteropancreatic NEC (GEP NEC)... | 110 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07488923) |
| March 6, 2026 | NCT07454642 | AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors | Avacta Life Sciences Ltd | Phase 1 | Recruiting | Vulvar Adenocarcinoma, PDAC - Pancreatic Ductal Adenocarcinoma, Gastric Adenocarcinoma, GEJ Adenocarcinoma, Cervical... | 174 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07454642) |
| February 20, 2026 | NCT07424547 | Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors | Conjupro Biotherapeutics, Inc. | Phase 1 | Recruiting | Cancer, Solid Tumor Cancer, Advanced Metastatic Cancer, Prostate, Small Cell Lung Cancer, Ovarian Cancer, Breast Cancer | 386 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07424547) |
| February 6, 2026 | NCT07391670 | A Phase I Dose Escalation and Dose Expansion Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Durvalumab | AstraZeneca | Phase 1 | Recruiting | Solid Tumours | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07391670) |
| November 25, 2025 | NCT07249879 | This Study is an Open-lable, Early Study to Evaluate the Safety, Feasibility, Cytokinetics, and Preliminary Efficacy of GC511B in DLL3+... | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 1 | Recruiting | Relapsed/Refractory Small Cell Lung Cancer | 55 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07249879) |
| November 17, 2025 | NCT07231445 | Study of ZG006 in Combination With PD-1/PD-L1 Immune Checkpoint Inhibitors as First-Line Standard Therapy in Participants With Extensive... | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Phase 1 | Recruiting | Small Cell Lung Cancer | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07231445) |
| November 14, 2025 | NCT07229313 | A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors | Kivu Bioscience Inc. | Phase 1 | Recruiting | Advance Solid Tumors | 76 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07229313) |
| September 17, 2025 | NCT07177937 | A Study of DXC014 in Patients With Advanced Solid Tumors. | Hangzhou DAC Biotechnology Co., Ltd. | Phase 1 | Recruiting | Small Cell Lung Cancer, Melanoma, Prostate Cancer, Other Advanced Solid Tumors | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07177937) |
| August 7, 2025 | NCT07110363 | A Clinical Study of BT02 in Treating Patients With Advanced Lung Cancer | Biotroy Therapeutics | Phase 1 | Not yet recruiting | Advanced Malignant Solid Tumor, Advanced Lung Cancer, Non-Small Cell Lung Cancer, Small Cell Lung Cancer | 58 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07110363) |
| June 5, 2025 | NCT07006727 | Phase I Study of \[225Ac\]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors | Novartis Pharmaceuticals | Phase 1 | Recruiting | Small Cell Lung Carcinoma, Large Cell Neuroendocrine Carcinoma of the Lung, Neuroendocrine Prostate Cancer... | 116 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07006727) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| [Hansoh BioMedical R&D Company](https://specstream.ai/data/clinical-trials/company/hansoh-biomedical-r-and-d-company) | 2 |
| [Amgen](https://specstream.ai/data/clinical-trials/company/amgen) | 2 |
| [Novartis Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/novartis-pharmaceuticals) | 2 |
| Memorial Sloan Kettering Cancer Center | 2 |
| National Cancer Institute (NCI) | 2 |
| [Suzhou Zelgen Biopharmaceuticals Co.,Ltd](https://specstream.ai/data/clinical-trials/company/suzhou-zelgen-biopharmaceuticals-co-ltd) | 2 |
| [Innovent Biologics (Suzhou) Co. Ltd.](https://specstream.ai/data/clinical-trials/company/innovent-biologics-suzhou-co-ltd) | 2 |
| SystImmune Inc. | 2 |
| Conjupro Biotherapeutics, Inc. | 1 |
| Novelty Nobility, Inc. | 1 |
| Moonlight Bio, Inc | 1 |
| SciTech Development, Inc. | 1 |
| University Health Network, Toronto | 1 |
| [MacroGenics](https://specstream.ai/data/clinical-trials/company/macrogenics) | 1 |
| Biotroy Therapeutics | 1 |
| [Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/shanghai-fudan-zhangjiang-bio-pharmaceutical-co-ltd) | 1 |
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 1 |
| Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. | 1 |
| [Pfizer](https://specstream.ai/data/clinical-trials/company/pfizer) | 1 |
| [Sichuan Baili Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/sichuan-baili-pharmaceutical-co-ltd) | 1 |
| Second Xiangya Hospital of Central South University | 1 |
| Thena Biotech S.r.l. | 1 |
| [Boehringer Ingelheim](https://specstream.ai/data/clinical-trials/company/boehringer-ingelheim) | 1 |
| Biokin (Shanghai) Biopharmaceutical Co., Ltd. | 1 |
| [CSPC Megalith Biopharmaceutical Co.,Ltd.](https://specstream.ai/data/clinical-trials/company/cspc-megalith-biopharmaceutical-co-ltd) | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 22 |
| China | 17 |
| Australia | 8 |
| Japan | 5 |
| Spain | 5 |
| Poland | 4 |
| France | 4 |
| South Korea | 4 |
| Canada | 3 |
| Belgium | 2 |
| Germany | 2 |
| Switzerland | 2 |
| Turkey (Türkiye) | 2 |
| United Kingdom | 2 |
| Israel | 2 |
| Italy | 2 |
| Netherlands | 2 |
| Bulgaria | 1 |
| Russia | 1 |
| Georgia | 1 |
| Taiwan | 1 |
| Monaco | 1 |
| Sweden | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Prosthodontics practices in the United States](https://specstream.ai/data/businesses/prosthodontics-practices/united-states)
- [Door suppliers in the United States](https://specstream.ai/data/businesses/door-suppliers/united-states)
- [Siding contractors in the United States](https://specstream.ai/data/businesses/siding-contractors/united-states)
- [Fastener suppliers in the United States](https://specstream.ai/data/businesses/fastener-suppliers/united-states)
- [Tiling contractors in the United States](https://specstream.ai/data/businesses/tiling-contractors/united-states)
- [Hawaiian restaurants in the United States](https://specstream.ai/data/businesses/hawaiian-restaurants/united-states)
